Tirzepatide: First Approval-Reference-Cited by-同舟云学术

Tirzepatide: First Approval

Published:2022-07 Issue:11 Volume:82 Page:1213-1220
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Syed Yahiya Y.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40265-022-01746-8.pdf

Reference25 articles.

1. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.

2. Eli Lilly and Company. Medicines in development: molecule & potential indication data as of April 28, 2022. https://www.lilly.com/discovery/clinical-development-pipeline. Accessed 23 June 2022.

3. Eli Lilly and Company. Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 [media release]. https://www.lilly.com/. Accessed 28 Apr 2022.

4. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225.

5. Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021;12(1):143–57.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tirzepatide administration improves cognitive impairment in HFD mice by regulating the SIRT3-NLRP3 axis;Endocrine;2024-09-02

2. Tirzepatide and exercise training in obesity;Clinical Hemorheology and Microcirculation;2024-08-14

3. Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment;Pharmaceuticals;2024-07-26

4. Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity;Scientific Reports;2024-07-19

5. Tirzepatide alleviates oxidative stress and inflammation in diabetic nephropathy via IL-17 signaling pathway;Molecular and Cellular Biochemistry;2024-07-04